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I.  INTRODUCTION 
Recently, the Federal Circuit and lower courts have applied a new 
test to assess the question of obviousness for chemical compounds.  
While courts have always considered the presence of some lead 
compound to be relevant to the question of obviousness, beginning at 
the turn of the millennium, the Federal Circuit began assessing 
obviousness in a more formulaic fashion, applying what is commonly 
referred to as the lead compound analysis to determine if a litigant has 
 
  *   B.S., Biochemistry, Kansas University, 2005; M.S., Chemistry, Kansas 
University, 2008; J.D. Marquette University School of Law, 2011.  Thanks to Professor Kali 
Murray for her assistance in writing this article.  Thanks as well to my family and, in 
particular, to my husband, Steve. 
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established a prima facie case of obviousness. 
This Paper describes the development of the lead compound 
analysis,1 and its application.2  This Paper then discusses some of the 
shortcomings and weaknesses of the doctrine’s applications3 and how 
understanding the lead compound analysis and how it is likely to be 
applied in typical situations can be useful in understanding both how to 
draft stronger patents and what ways might be available to attack the 
obviousness of a chemical compound or a court’s application of the lead 
compound analysis.4 
A.  Obviousness and Chemical Compounds 
While the obviousness analysis has always been factually intensive, 
the parameters for assessing obviousness have remained relatively 
steady since the United States Supreme Court first addressed 
obviousness under the 1952 Patent Act in Graham v. John Deere 
Company.5  In Graham v. John Deere the Supreme Court laid out four 
factors for approaching obviousness.  First, the scope and the content of 
the prior art and the claims should be determined.6  Second, the 
differences between the prior art and the claims at issue must be 
ascertained.  Third, the level of ordinary skill in the art is determined.  
And finally, courts consider additional factors such as the commercial 
success, long felt but unresolved needs, and failure of others.7 
The Supreme Court’s most recent take on obviousness emphasized 
that the John Deere factors still defined the controlling inquiry.8  In KSR 
v. Teleflex, the Supreme Court held that the Federal Circuit’s teaching 
suggestion motivation (TSM) test was overly rigid and the Court 
emphasized that any approach to obviousness must be a flexible 
approach.9  Under the TSM test, the Federal Circuit would determine 
obviousness of a combination by looking to see if the prior art had some 
teaching, suggestion, or created some motivation to combine certain 
elements in the way that the invention did.10  If a court found that the 
 
1.  See infra Part IA–IB. 
2.  See infra Part IC. 
3.  See infra Part II. 
4.  See infra Part III. 
5.  Graham v. John Deere Co. of Kansas City, 383 U.S. 1 (1966). 
6.  Id. at 17–18. 
7.  Id.  
8.  KSR Int’l Co. v. Teleflex, Inc., 550 U.S. 398 (2007). 
9.  Id. at 419. 
10.  Id. at 418. 
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prior art did contain a teaching, suggestion or motivation, the invention 
would be obvious. 
The TSM test was a high standard for proving obviousness of a 
chemical compound because it required the prior art to contain 
language not often found, suggestions of what could be done.  KSR 
lowered the standard for asserting obviousness, holding that the Federal 
Circuit’s standard was not the only approach to obviousness, and that 
using it alone constituted too rigid of an analysis.  After KSR, while a 
teaching suggestion or motivation might be relevant, lower courts are 
free to look at things outside the prior art, such as common sense and 
ordinary creativity.11 
In the earliest cases at the Court of Customs and Patent Appeals 
(C.C.P.A.) specific to chemical compounds, structural similarity was 
deemed as sufficient to support a finding of obviousness.12  A person 
who knew the structure of a related compound would then, in turn, be 
motivated to make analogs of that compound.  However, as technology 
for elucidating structures came on the market, and more structures 
became known, courts, perhaps recognizing the complexity and 
unpredictability of chemical compounds,13 moved away from the 
assumption that once a structure was known, it would be obvious to test 
all the analogs for similar properties. 
In the 1970s, the C.C.P.A. found that prior art disclosure of a 
structural analog alone was insufficient to provide real motivation to 
make a new compound.14  In Stemniski, the applicant claimed a tin 
composition useful in lubricants as an antioxidant while the prior art 
analog compositions had no known utility.15  The court decided that 
without a known utility for the prior art compound, the applicant had no 
 
11.  Id. at 420 (“Common sense teaches, however, that familiar items may have obvious 
uses beyond their primary purposes, and in many cases a person of ordinary skill will be able 
to fit the teachings of multiple patents together like pieces of a puzzle.”). 
12.  See, e.g. In re Riden, 318 F.2d 761 (C.C.P.A 1963); In re Henze, 181 F.2d 196 
(C.C.P.A. 1950). 
13.  Indeed, there are several examples of chemical compositions that are structurally 
similar, but have widely diverging properties.  A common example is thalidomide, a drug 
developed in the 1950s.  The drug contained two enantiomers, which are compounds that 
differ only in their configuration at one site, that is, the atoms have the exact same 
configuration. One enantiomer of thalidomide helped people suffering from insomnia to 
sleep, however, the other enantiomer caused deformities in unborn children of the patients 
who took the drug.  See GARETH THOMAS, MEDICINAL CHEMISTRY: AN INTRODUCTION, 38 
(2d ed. 2007). 
14.  In re Stemniski, 444 F.2d 581, 581 (C.C.P.A. 1971). 
15.  Id. at 582. 
BARRON- FORMATTED (DO NOT DELETE) 4/10/2012  1:11 PM 
404  MARQ. INTELL. PROP. L. REV. [Vol. 16:2 
 
reason or motivation to synthesize the claimed analogs.16  It was also 
immaterial that the prior art compounds actually had these properties 
since they were unknown at the time of invention.17 
A subsequent line of cases confirmed Stemniski.18  These cases 
mainly conclude that some utility is required for the prior art compound 
to give a person of ordinary skill in the art the requisite motivation to 
synthesize analogs.19  This new approach not only allowed for the 
patenting of a large number of chemical compounds, but also confirmed 
the idea that structural similarity for chemical compounds is more 
unpredictable than the structural similarity of other systems.  For 
example, two mechanical structures with a substantially similar structure 
are likely to operate in the same way, but chemical compounds do not 
operate under this same assumption.  In contrast, chemical compounds 
display a wide range of properties from their steric effects to the 
electronic effects of substitutions, as well their interactions with chiral 
systems such as the body. 
With the switch from the C.C.P.A. to the Federal Circuit, the 
Federal Circuit considered what is still considered a lead case for the 
obviousness of structurally similar chemical compounds en banc in In re 
Dillon.20  In Dillon, a patent applicant claimed a composition of 
hydrocarbon fuel and tetra-orthoester, producing less soot during 
combustion, but the prior art disclosed the use of tri-orthoesters in fuel 
for dewatering purposes and of tetra-orthoesters as water scavengers in 
hydraulic fluids.  Tri-ortho esters differ from tetra-ortho esters in the 
addition of one ester group to the compound.  The Board of Patent 
Appeals and Interferences found that the claims were prima facie 
obvious in light of the prior art.21  The court found that the “sufficiently 
close relationship” between the tri-orthoesters and the tetra-ortho-
esters and the knowledge within the prior art created an expectation 
that the tetra-esters would have the same or similar properties as the tri-
esters.22 
The Federal Circuit summarized the analysis as having different 
considerations: (1) “the new compound or composition [must be] [] 
 
16.  Id. at 587. 
17.  Id.  
18.  See, e.g., In re Gyurik, 596 F.2d 1012, 1018 (C.C.P.A. 1979) (noting that a structural 
analog was not obvious based on a reaction intermediate). 
19.  Id.  
20.  In re Dillon, 919 F.2d 688 (Fed. Cir. 1990). 
21.  Id. at 692. 
22.  Id. 
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structurally similar to the reference compound or composition,” and (2) 
that “there is some suggestion or expectation in the prior art that the 
new compound or composition [would] [] have the same or similar utility 
as [the compound asserted by the applicant] [].”23 If  the previously 
disclosed properties of a prior art compound provided sufficient 
motivation to trigger a prima facie obviousness rejection, even though 
the new compound has unrelated, different, and unexpected properties, 
the analysis then turns to rebuttal, by showing that his compound has 
unexpected properties relative to prior art compounds, “that the prior 
art was so deficient that there was no motivation to make what 
otherwise might appear to be obvious changes,” or any other pertinent 
argument.24   
B. Development of Lead Compound Analysis 
The earliest case establishing the modern “lead compound” analysis 
is Yamanouchi Pharm. Co. v. Danbury Pharmacal, Inc.25  Yamanouchi 
was the result of a successful motion for judgment as a matter of law 
(JMOL) upholding the validity of the ‘408 patent.26  The ‘408 patent was 
directed at compounds that inhibit gastric acid secretion.27  At issue was 
a claim for the compound famotidine.28  Famotidine is a member of a 
larger class of compounds called histamine2 (H2) antagonists, which have 
a general structure containing a substituted heterocycle which is 
connected to a polar tail by an “alkyl containing” chain.29  Danbury filed 
an Abbreviated New Drug Application (ANDA) with the Food and 
Drug Administration (FDA) and made a Paragraph IV certification that 
the patent on famotidine was invalid.30  Paragraph IV certifications are 
considered acts of infringement,31 and after receiving the certification, 
Yamanouchi filed suit. 
At the district court, Danbury argued that famotidine was invalid as 
an obvious result of combining features of compounds from the prior 
art, and then performing a bioisosteric substitution to reach resulting 
 
23.  Id. 
24.  Id. at 692–93. 
25.  Yamanouchi Pharm. Co. v. Danbury Pharmacal, Inc., 231 F.3d 1339 (Fed. Cir. 
2000). 
26.  Id. at 1341. 
27.  Id.  
28.  Id.  
29.  Id. 
30.  Id. at 1342. 
31. 35 U.S.C. § 271 (e)(2) (2010). 
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compound.32  Specifically, Danbury presented two H2 antagonists from 
the prior art, tiotidine and E44, and argued that famtotidine was the 
result of combining the heterocylce of tiotidine with the polar tail of E44 
followed by a routine bioisosteric substitution of a sulfomoyl group for a 
carbamoyl group substitution in the polar tail.33  
  The Federal Circuit upheld the JMOL noting at the outset that 
Danbury did not show the motivation for selecting either of the 
compounds.34  While the E44 showed increased activity, the court noted 
that the activity alone was not a sufficient motivation to choose E44 as a 
lead compound because other compounds had been shown to be more 
active.35  The court further noted that Danbury had failed to show the 
motivation to combine the heterocycle of tiotidine with the polar tail of 
E44.36  An expectation that the compound would show baseline H2 
antagonist activity was not enough to show the reasonable expectation 
of success for the compound.37  Finally, the court noted that the prior art 
did not suggest any order of manipulating the compounds, so there was 
no teaching that would have led a person having ordinary skill in the art 
to follow the steps of combining the two parts of different molecules, 
then making the bioisosteric substitution. 
 
 
The analysis in Yamanouchui was applied again in Eli Lilly & Co. v. 
Zenith Goldline Pharm., Inc.; however, in Lilly the analysis of 
Yamanouchi was transformed into a requirement.  In Lilly, IVAX 
Pharmaceuticals, Inc. (formerly Goldline) filed an ANDA Paragraph IV 
 
32.  Yamanouchi, 231 F.3d at 1343–44. 
33.  Id. 
34.  Id. at 1345. 
35.  Id. 
36.  Id. 
37.  Id. 
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certification to make Lilly’s Zyprexa.  IVAX asserted that Lilly’s patent 
on the active ingredient in Zypreza, olanzapine, was invalid as obvious.38 
IVAX argued that olanzapine was obvious based on a prior art 
reference to ethyl olanzapine.  Ethyl olanzapine has a similar structure 
to olanzapine differing only in that ethyl olanzapine has an ethyl rather 
than a methyl group on the thiophene ring. 
 
 
IVAX argued that the structural similarity made them prima facie 
obvious, but the district court rejected IVAX’s arguments.  Instead, the 
district court applied the two step analysis from Yamanouchi to 
determine whether there was a prima facie case of obviousness.39  On 
appeal, IVAX argued that the district court had erred by requiring as a 
“threshold requirement” a teaching or incentive to treat the closest 
prior art as a lead compound.40  The Federal Circuit affirmed the 
decision below and likened the case to Yamanouchi; however, unlike 
the district court, the Federal Circuit did not cite Yamanouchi as the 
source of its two step analysis. Despite not citing Yamanouchi in the 
same way as the district court, the Federal Circuit undertook the same 
analysis as the district court finding first that IVAX had failed to prove 
that ethyl olanzapine was the lead compound.  Despite its structural 
similarity, the prior art had taught that an electron withdrawing group 
on the benzene ring improved activity.41  Next, the court further noted 
that even if ethyl olanzapine would have been a lead compound, the law 
required motivation to modify the prior art compound into the claimed 
invention.42  
 
38.  See Eli Lilly & Co. v. Zenith Goldline Pharm., Inc., 471 F.3d 1369, 1380 (Fed. Cir. 
2006). 
39.  Eli Lilly & Co. v. Zenith Goldline Pharm., Inc, 364 F. Supp. 2d 820, 904 (S.D. Ind. 
2005).   
40.  Eli Lilly & Co. v. Zenith Goldline Pharm., Inc., 471 F.3d 1369, 1377 (Fed. Cir. 
2006). 
41.  Id. at 1374. 
42.  Id. at 1379. 
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  The Federal Circuit gave more clarity to the new requirement in 
Takeda Chemical Industries, Ltd v. Alphapharm.  In Takeda, 
Alphapharma challenged the validity of Takeda’s patent on 
Thiazolidinedione derivates on the grounds of 
obviousness.43  Thiazolidinedione compounds (TZDs) are a class of 
compounds which were first discovered to be useful for the treatment of 
Type 2 diabetes because they have biological activity against insulin 
resistance. Claim 2 of the patent referred to pioglitazone, which later 
became the active ingredient of Takeda’s drug ACTOS, which is used to 
control blood sugar in patients with Type 2 diabetes.44 
Alphapharm’s validity challenge rested on a prior art reference, 
compound b, which showed a compound that differed from pioglitazone 
in that the pyridyl ring was substituted with a methyl rather than an 
ethyl, and that the substitution was at the six position of the ring, rather 
than at the five position.45  The district court ruled in favor of Takeda 
finding that the claims were not obvious because there was no 
motivation to select compound b as the lead compound for antidiabetic 
research and that the prior art taught away from its use.46 
 
 
Alphapharm appealed, arguing that the lower court misapplied the 
holding of In re Dillon, which said that the structural similarity between 
compounds could create a prima facia case of obviousness.  The Federal 
Circuit elaborated on the requirements of structural similarity, noting 
that “[s]tructural relationships may provide the requisite motivation or 
suggestion to modify known compounds to obtain new compounds” but 
a prima facie case of unpatentability required “a showing that the prior 
art would have suggested making the specific molecular modifications 
 
43.  Takeda Chem. Indus., Ltd. v. Alphapharm Pty., Ltd., 492 F.3d 1350, 1354 (Fed. 
Cir. 2007). 
44.  Id. at 1353–54. 
45.  Id. at 1354. 
46.  Id. 
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necessary to achieve the claimed invention.”47  The court then restated 
saying, “in cases involving new chemical compounds, it remains 
necessary to identify some reason that would have led a chemist to 
modify a known compound in a particular manner to establish prima  
facie obviousness.”48 
Applying this rule to the facts at issue, the court found that 
Alphapharm had failed to make a showing that compound b would have 
been selected as a lead compound.  The court clarified that by lead 
compound, Alphapharm was referring to “a compound in the prior art 
that would be most promising to modify in order to improve 
upon.”49  The court looked at several prior art references, some of which 
suggested that compound b was particularly important, and some of 
which did not.  The court found that as a whole, the person of ordinary 
skill in the art would not have selected compound b as a lead 
compound.50  The court went on to note that even if Alphapharm had 
established the preliminary finding that compound b was a lead 
compound, there was nothing in the prior art that suggested the 
modifications of changing the ethyl substituent to the methyl substituent 
and moving the placement of the substituent.51 
Subsequent cases cite Takeda for the required lead compound 
analysis; however, commentators have suggested that the true origin of 
the required showings stems from Yamanouchi, where the obviousness 
challenge was so absurd that the court was merely pointing out in dicta 
the flawed logic of the challenging party.52  Dicta or not, the lead 
compound analysis has taken firm root with several other Federal 
Circuit cases applying the doctrine and cases at the district court level as 
well.53 
 
47.  Id. at 1356 (quoting In re Deuel, 51 F.3d 1552, 1558 (Fed. Cir. 1995)). 
48.  Id. at 1357 (emphasis added). 
49.  Id. 
50.  Id. at 1360. 
51.  Id. at 1361. 
52.  Vincent Capuano, Obviousness of Chemical Compounds: The “Lead Compound” 
Concept, INTELLECTUAL PROPERTY TODAY,  July 2007, at 33. 
53.  See Proctor & Gamble Co. v. Teva Pharm., USA, Inc., 566 F.3d 989 (Fed. Cir. 
2009); Sanofi-Synthelabo v. Apotex, Inc., 550 F.3d 1075 (Fed. Cir. 2008); Ortho-McNeil 
Pharm., Inc. v. Mylan Lab., Inc., 520 F.3d 1358 (Fed. Cir. 2008); Eisai Co. Ltd v. Dr. Reddy 
Lab., 533 F.3d 1353 (Fed. Cir. 2008); Altana Pharma AG v. Teva Pharm. USA, Inc., 566 F.3d 
999 (Fed. Cir. 2009); Pfizer, Inc. v. Apotex, Inc., 488 F.3d 1377 (Fed. Cir. 2007);  Eli Lilly & 
Co. v. Sicor Pharm., Inc., 705 F. Supp. 2d 971 (S.D. Ind. 2010); Pfizer Inc. v. IVAX Pharm., 
Inc., No. 07-CV-00174 DMC, 2010 WL 339042 (D.N.J.); Sanofi Aventis Deutschland GMBH 
v. Glenmark Pharm., Inc., No. 07-CV-5855DMC, 2010 WL 2428561 (D.N.J.); Unigene Lab., 
Inc. v. Apotex, Inc., No. 06 CV.5571 2009 WL 2762706 (S.D.N.Y.); Eli Lilly & Co. v. Actavis 
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C.  Current Application of the Lead Compound Analysis 
Since its development several cases have shed light on the nuances 
of the lead compound analysis.  In its simplest form, in order to find a 
chemical compound obvious, a party must prove first that a person of 
ordinary skill would have selected the compound as a lead compound. 
Second, it must be proved that the person of ordinary skill in the art 
would have had some motivation to modify the lead compound. Finally, 
a court will weigh rebuttal evidence.  The nuances, as well as some gaps 
in the doctrine have been shown by subsequent case law where the 
doctrine has been invoked.54 
1. Selection of the Lead Compound 
The party challenging the obviousness of a chemical composition 
must first establish a lead compound.55  The Federal Circuit defined lead 
compound in Takeda as a compound in the prior art that would be 
“most promising to modify” to obtain better activity.56  A compound 
which has been singled out in its field is more likely to be considered to 
be a lead compound; whereas negative side effects can sway the court 
against finding that the compound was a lead compound.  A party 
challenging obviousness is more likely to prevail when there are a small 
number of lead compounds, but is not limited to a single lead 
compound.57 
In Altana Pharma AG v. Teva Pharmaceuticals USA, Inc., the 
Federal Circuit affirmed a district court’s determination that a 
compound was a lead compound because the compound was identified 
as the most active in the field.58  The dispute centered around Altana’s 
 
Elizabeth LLC, 676 F.Supp. 2d 352 (D.N.J.); Merck Sharp & Dohme Pharm. v. Teva Pharm. 
USA, Inc., No. 07-1596 2009 WL 3153316 (D.N.J.); Bayer AG v. Dr. Reddy’s Lab., Ltd., 518 
F. Supp. 2d. 617 (D. Del. 2007);  Daiichi Sankyo Co. Ltd. v. Mylan Pharm., Inc., 670 F. Supp. 
2d. 359 (D.N.J.); In re ’318 Patent Infringement Litigation, 583 F.3d 1317 (Fed. Cir. 2009); 
Novartis Pharms. Corp. v. Teva Pharm. USA, Inc., No. 05-CV-1887, 2007 WL 2669338 
(D.N.J); Pfizer v. Teva Pharms. USA, Inc., 482 F. Supp. 2d. 390 (D.N.J.); Janssen Pharm. v. 
Mylan Pharm., Inc., 456 F. Supp. 2d 644 (D.N.J.). 
54.  See infra Section II. 
55.  Contentions by parties to the contrary have been rejected by courts.  In Bayer AG 
v. Dr. Reddy’s Laboratories, Dr. Reddy’s attempted to argue that it did not need to establish 
a lead compound and did not have any testimony on the subject.  The court disagreed and 
required a lead compound.  518 F. Supp. 2d 617, 626–27 (D. Del. 2007).   
56.  See Takeda Chem. Indus., Ltd. v. Alphapharm Pty., Ltd., 492 F.3d 1350, 1357 (Fed. 
Cir. 2007).   
57.  Eisai Co. Ltd v. Dr. Reddy’s Lab., Ltd., 533 F.3d 1353 1358–59 (Fed. Cir. 2008). 
58.  Altana Pharma AG v. Teva Pharms. USA, Inc., 566 F.3d 999, 1008 (Fed. Cir. 
2009). 
BARRON- FORMATTED (DO NOT DELETE) 4/10/2012  1:11 PM 
2012]          STRUCTURAL UNCERTAINTY 411 
 
patent on pantoprazole, the active ingredient in, PROTONIX®.59  
Pantoprazole is a proton pump inhibitor (PPI) and was developed after 
AstraZeneca had successfully marketed another PPI, omeprazole.60  
Teva argued that the patent on pantoprazole was invalid in light of both 
Altana’s own patent disclosing a similar compound, compound 12, and 
AstraZeneca’s patent on omeprazole.61  The district court found that a 
person of ordinary skill in the art would have selected compound 12 as a 
lead compound.62  The Federal Circuit affirmed, finding that the district 
court’s decision was not clearly erroneous,63 despite the fact that Altana 
produced evidence that there were concerns about the toxicity of 
compound 12, and that there were over ninety other compounds 
disclosed by the prior art.64  The district court based its decision on 
evidence that compound 12 was the natural choice for further 
development because it had a higher potency than any of the other 
compounds.65 
The opposite decision was reached in Takeda v. Alphapharm where 
the parties presented multiple prior art references.66  Some of the 
references identified compound 12 as important, while other references 
identified different compounds as important.  The court also found 
references discussing the side effects of compound 12 noting that 
“negative properties . . . would have directed one of ordinary skill in the 
art away from that compound.”67 
The number of potential lead compounds is also important to the 
lead compound analysis.  In Ortho-McNeil Pharmaceutical v. Mylan, 
Mylan challenged Ortho-McNeil’s patent on topiramate.68  Although 
topiramate’s anticonvulsant properties had been discovered by chance 
while a scientist was looking for a diabetes drug, Mylan argued that a 
 
59.  Id. at 1002. 
60.  Id. at 1003. 
61.  Id. at 1004–05. 
62.  Id. at 1005. 
63.  Id. at 1010. 
64.  Id. at 1008. 
65.  Id. (“Although potency is not dispositive, the district court believed–not 
unreasonably–that the potency of the compound was a factor that would have led one of skill 
in the art to select compound 12 from the group for further study. It bears mention that 
Altana itself had selected compound 12 for further development efforts.”). 
66.  Takeda Chem. Indus., Ltd. v. Alphapharm Pty., Ltd., 492 F.3d 1350 (Fed. Cir. 
2007). 
67.  Id. at 1359. 
68.  Ortho-McNeil Pharm. Inc. v. Mylan Lab., Inc., 520 F.3d 1358, 1361 (Fed. Cir. 
2009). 
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person of ordinary skill in the art of searching for a diabetes drug would 
have found topiramate.  The Federal Circuit disagreed stating that, 
“[t]he record . . . does not present a finite (and small in the context of 
the art) number of options.” But that an “easily traversed, small and 
finite number of alternatives . . . might support a conclusion of 
obviousness.”69 
While a small number of lead compounds can be advantageous in 
convincing a court that the person of ordinary skill would have selected 
a lead compound, parties are not limited to only one lead compound.  In 
Eisai v. Dr. Reddy’s Laboratories, Ltd, Teva, along with Dr. Reddy’s, 
challenged Eisai’s patent on rabeprazole, a proton pump inhibitor 
developed in the wake of the commercial success of omeprazole.70  
Teva’s invalidity claim rested on both omeprazole and another 
compound.71  After the district court found rabeprazole nonobvious, 
Teva appealed, arguing that the district court erred in making it choose 
a single lead compound.  The Federal Circuit contended that Teva, not 
the district court, chose to limit its case to a single lead compound and 
again noted that the prima facie case for non-obviousness was consistent 
with KSR.72 
2.  Motivation to Modify the Lead Compound 
Once a lead compound has been established, the party asserting that 
a chemical compound is obvious must show some motivation to modify 
the lead compound in a way that results in the compound at issue.73  The 
motivation to modify the lead compound can come from an explicit 
teaching in the prior art, or can be gleaned from the prior art as a whole.  
As with the selection of the lead compound, the number of possibilities 
for modification can be important; however, the modification cannot be 
the result of mere routine testing.  Finally, to make the prima facie case 
of obviousness, there must be some reasonable expectation that the 
modification will work. 
Motivation to modify a prior art compound can come from explicit 
references in the prior art.  In Altana Pharma AG v. Teva 
Pharmaceuticals, the Federal Circuit affirmed the district court’s finding 
that articles within the prior art would have led a person to modify the 
 
69.  Id. at 1364. 
70.  Eisai Co. v. Dr. Reddy’s Lab., Ltd., 533 F.3d 1353, 1360 (Fed. Cir. 2008). 
71.  Id. at 1357. 
72.  Id. at 1358–59. 
73.  Takeda Chem. Inds., Ltd. v. Alphapharm Pty., Ltd., 492 F.3d 1350, 1357 (Fed. Cir. 
2007).   
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asserted lead compound.74  One of the prior art articles suggested that a 
pKa of 4 would be most desirable for a proton pump inhibitor because it 
would improve the stability prior to the compounds introduction to the 
parietal cells in the stomach.75  Another reference suggested that the 
specific substitution made in transforming the lead compound, 
substituting a methoxy group for a methyl group would provide a lower 
pKa.  The Federal circuit found that this evidence supported the district 
court’s finding that a person of ordinary skill in the art would have 
found the modifications to the lead compound obvious.76 
Courts have also found motivation to alter the lead compound in the 
absence of a specific teaching.  In Pfizer v. Apotex, Apotex challenged 
the validity of Pfizer’s patent on the compound amlodipine besylate.77  
Amlodipine besylate is the besylate salt of amlodipline, a compound 
which had previously been patented.78  The prior art also discussed 
pharmacologically acceptable salts of amlodipine, but never the besylate 
salt specifically.79  The Federal Circuit overturned the district court’s 
finding of non-obviousness.  The Federal Circuit noted that consistent 
with KSR, motivation could “be gleaned” from the prior art as a whole.  
There were a limited number of pharmacologically acceptable salts, and 
besylate was known to have favorable properties; thus, a person of 
ordinary skill in the art would have found it obvious to modify 
amlodipine to its beslyate salt. 
 
 
In Pfizer v. Apotex, the court also noted that the discovery of the 
 
74.  Atlana Pharma AG v. Teva Pharm. USA, Inc., 566 F.3d 999, 1008 (Fed. Cir. 2009).   
75.  Id. at 1004.   
76.  Id. at 1010.   
77.  Pfizer, Inc. v. Apotex, Inc., 480 F.3d 1348, 1352 (Fed. Cir. 2007). 
78.  Id. at 1353. 
79.  Id. at 1361. 
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besylate was the product of routine testing and thus did not meet the 
standards of patentability.  While the court noted that in the last 
sentence of 35 U.S.C. § 103, “[p]atentability shall not be negatived by 
the manner in which the invention was made,”80 the court noted that 
consideration of the “routine testing” by Pfizer was appropriate because 
it provided both the means and the likely results of trying the compound 
with acceptable salts.81  The court likened the choosing of the salt to 
optimization of a reaction which flows from the “‘normal desire of 
scientists . . . to improve upon what is already . . . known.’”82 
3.  Likelihood of Success 
Finally, the cases have also established that in addition to the 
motivation to modify the lead compound, there must be some likelihood 
of success in modifying the lead compound.  A showing that the field 
was highly unpredictable can weigh against a prima facie case. 
In Proctor & Gamble v. Teva Pharmaceuticals, Teva challenged P & 
G’s patent on the compound risedronate as obvious in light of another 
patent that disclosed thirty-six other molecules for preventing bone 
resorption.83  Teva argued that the structural similarity between 
risedronate and the prior art compound, 2-pyr EDHP would have made 
risedronate obvious to a person of ordinary skill in the art.84 
 
 
Risedronate and 2-pry EHDP are positional isomers, differing in the 
placement of only position.  The district court found that 2-pyr-EHDP 
was not likely to be selected as a lead compound because there were a 
 
80.  35 U.S.C. § 103 (2010). 
81.  Pfizer, 480 F.3d at 1367. 
82.  Id. at 1368. 
83.  Proctor & Gamble Co. v. Teva Pharm. USA, Inc., 566 F.3d 989, 993 (Fed. Cir. 
2009). 
84.  Id. 
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number of other compounds disclosed in the ‘406 patent, and 2-pyr 
EDHP was not specifically claimed.85  Other prior art had suggested the 
concept of testing the positional isomers but the court found that these 
modifications would not have been obvious in the field of 
bisphosponates due to their unpredictability.86 The Federal Circuit 
affirmed, while the court noted that a compound may provide the 
motivation to try its isomer, analog or homolog, in this case there was 
insufficient evidence for a person of ordinary skill to test risedronate 
due to the unpredictability of the field.87  The court concluded that Teva 
had also failed to show that a person of ordinary skill in the art would 
have had a reasonable expectation of success in synthesizing 
risedronate.88 
In Pfizer v. Apotex, the court overturned the district court’s finding 
that a skilled artisan would not have had a reasonable expectation of 
success in making the besylate salt of amlodipine.  Pfizer had presented 
evidence at the trial that there was no reliable way to predict whether a 
salt would form and what its exact properties would be.  The court 
noted that “obviousness cannot be avoided simply by a showing of some 
degree of unpredictability in the art so long as there is some reasonable 
probability of success.”89 
A compound’s unexpected positive properties can rebut the 
presumption.  In Sanofi-Synthelabo v. Apotex, the court found that a 
patent for a single enantiomer of a lead compound was not obvious 
because the separation produced unexpected results.90  The compound 
at issue in Sanofi-Synthelabo was the d-enantiomer of clopidogrel 
bisulfate.  The racemic mixture of clopidogrel had previously been 
patented by Sanofi-Synthelabo.  The court found that the racemate 
would have been identified as a lead compound by a person of ordinary 
skill in the art despite problems with its toxicity.91  Sanofi-Synthelabo 
decided to undertake the separation of the enantiomers and found 
absolute stereoselectivity, meaning that the d-enantiomer showed all the 
favorable therapeutic activity while the l-enantiomer showed all of the 
 
85.  Proctor & Gamble Co, v. Teva Pharm. USA, Inc., 536 F. Supp. 2d. 476, 495 (D. 
Del. 2008).    
86.  Id.    
87.  Proctor & Gamble Co., 566 F.3d at 995. 
88.  Id. at 996. 
89.  Id. at 1364. 
90.  Sanofi-Synthelab v. Apotex, 550 F.3d 1075, 1090 (Fed. Cir. 2008). 
91.  Id. at 1080. 
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toxicity.92 
Apotex appealed arguing that the district court had applied an 
incorrect legal standard and should have asked not whether the results 
were unexpected, but rather, whether or not it would be obvious to try 
to separate the enantiomers.93  The Federal Circuit affirmed, noting that 
a person of ordinary skill would not have expected absolute 
stereoselectivity.94 
The opposite result was reached when stereoisomers were separated 
in the absence of unexpected results.  In Aventis Pharma Deutschland 
GMBH v. Lupin, Ltd., a claim to the pure S enantiomer of a ACE 
inhibitor was found to be obvious.95  The prior art had disclosed related 
ACE inhibitors and the fact that the all-S configurations were more 
potent.96  The court determined that the patent was obvious.97 
Finally, if the case of obviousness is sufficiently strong, no rebuttal 
evidence will be able to overcome it.  In Pfizer v. Apotex, after finding 
that a prima facie case of obviousness for amlodipine besylate had been 
made, the Federal Circuit rejected Pfizer’s argument that unexpected 
results overcame the prima facie case.  The court noted that even if 
Pfizer had presented unexpected results, it would not have overcome 
the strong case of obviousness.98 
II.  PROBLEMATIC ASPECTS OF LEAD COMPOUND ANALYSIS 
The lead compound analysis is problematic in several ways.  First, 
lower courts are often confused by the test, and its limits are not well 
understood.  Second, the test is exactly the type of rigid application that 
the Supreme Court warned against in KSR v. Teleflex.  Moreover, the 
test fails to consider some of the realities of drug development in 
important aspects such as synthesis. 
Several aspects of its application are still problematic even as the 
lead compound analysis is becoming more solidified in the case law.  
One main problem with the test is that its limits are not clearly defined 
by the Federal Circuit and lower courts have applied the doctrine to 
cases where it is not clear that structural similarity is more at issue or at 
 
92.  Id. at 1081. 
93.  Id. at 1089. 
94.  Id. at 1087. 
95.  Aventis Pharma Deutschland GMBH v. Lupin, Ltd., 499 F.3d 1293, 1294–95 (Fed. 
Cir. 2007). 
96.  Id. at 1296. 
97.  Id. at 1303. 
98.  Pfizer, Inc. v. Apotex, Inc., 480 F.3d 1348, 1381 (Fed. Cir. 2007). 
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least not the only issue. Another problem which has been addressed, but 
only in a cursory fashion, is whether the lead compound analysis, which 
is highly rigid and formulaic, comports with the requirements for any 
obviousness analysis from KSR, which is that the approach must be 
flexible. 
A.  Application to Combination Drugs 
In Sanofi-Aventis Deutschland GMBH v. Glenmark 
Pharmaceuticals, the District Court of New Jersey used the lead 
compound approach to assess the obviousness of a combination drug.99 
A combination drug, sometimes also called a fixed dose combination, 
combines two or more pharmaceutical agents in a single drug.100  Most 
pharmaceuticals traditionally have only one active ingredient.  
Combination drugs have become increasingly popular—some because 
the two drugs work synergistically, also doctors sometimes prefer 
combination drugs because they increase compliance.101 
In Sanofi Aventis Deuschland GMBH v. Glenmark Pharmaceuticals, 
Aventis sought to enjoin Glenmark from selling a generic form of 
Tarka®, a hypertension drug.  Tarka® combines trandolapril, 
immediate release angiotensin converting enzyme inhibitor, and 
verapamil hydrochloride, a slow release formulation of a calcium 
channel blocker. Thus, it has two separate components, whose 
structures are as follows. 
 
 
99.  Sanofi-Aventis Deutschland GMBH, v. Glenmark Pharm. Inc., USA, No. 07-CD-
5855 DMC, 2010 WL 2428561 (D.N.J.).    
100.  Popular examples of combination therapies include Symbyax® which combines 
Zyprexia® and Prozac®, and Caduet®, which combines Lipitor® for high cholesterol and 
Norvasc® for hypertension.  
101.  See Fing Pan et al., Impact of Fixed-Dose Combination Drugs on Adherence to 
Prescription Medications, 23(5) J. Gen. Internal Med., 611 (2008) (discussing the number of 
medications prescribed as one of many factors affecting patient compliance with a prescribed 
regimen). For a study of patients views on the benefits of combined pills versus multiple 
medications see generally B. Williams et al., Patient Perspectives on multiple medications 
versus combined pills: a qualitative study,  98 QJM 885 (2005).   
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Sanofi’s Patent claimed combinations of an angiotensin-converting 
inhibiter with calcium agonists in drugs.  Angiotensin converting 
enzyme is an enzyme in the body that mediates, vasoconstriction, by 
converting angiotensin I to angiotensin II and by degrading bradykinin, 
a vasodilator.102  An angiotension converting enzyme agonist is a 
molecule that binds to the Angiotensin converting enzyme to reduce its 
activity.  Several compounds act as ACE inhibitors,103 but the patent 
claimed a two specific ACE inhibitors quinapril and trandolapril.  
Calcium channel blockers disrupt the flow of Calcium ions in the body.  
In blood vessels, decreased calcium results in less contraction of the 
vessels and increase arterial flow.  Again, several compounds are known 
to act as calcium channel blockers and the patent was not restricted to 
any certain inhibitor.104 
In assessing Sanofi’s request for an injunction, the District Court for 
New Jersey applied the lead compound analysis in determining the 
 
102.  Boron Walter, Ph.D. Medical Physiology, A Cellular and Molecular Approach, 
886–87, 1059 (2003). 
103.  For example, benazepril, captopril, enalapril, fosinapril, lisinopril, moexipril, 
perindopril, quinapril, ramipril, trandolapril. 
104.  Sanofi-Aventis Deutschland GMBH, 2010 WL 2428561, at *11.  Examples 
include amlodipine, aranidipine, azelnidipine, barnidipine, benedipine, bepridil, clinidipine, 
clevidipine, diltazem, fendilinem, isradipine, efonidipine, felodipine, fluspirilene, gallopamil, 
lacidipine, lercanidipine, manidipine, mibefradil nicardipine, nifedipine, nivadipine, 
nimodipine, nisolidipine, nitrerdipine, pranidipine, verpamil.  
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likelihood of success on the merits.105  In assessing the likelihood of 
success on the defense of obviousness, the court invoked the lead 
compound analysis.  Citing Takeda, the court noted that “in cases 
involving new chemical compounds, . . . it remains necessary to identify 
some reason that would have led a chemist to modify a known 
compound in a particular manner to establish prima facie obviousness of 
a new claimed compound.”106  The court then went on to assess the 
relevant prior art, which included (1) a prior art reference suggesting the 
ACE inhibitor captopril with a calcium agonist, (2) a different ACE 
inhibitor, enalapril with a calcium agonist nifedipine, (3) a reference 
teaching that quinapril was “considerably more potent” than either 
elanopril or catopril.107 
The court found that the likelihood of success on the merits favored 
Glenmark, and that the prior art weighed toward a finding of 
obviousness.  While Sanofi asserted that there were important structural 
differences between enalapril, quinapril, and captopril,108 the court 
rejected this argument, but on the basis that the ‘244 patent did not 
purport to resolve the problems of structure or ACE or mechanism of 
action of the ACE inhibitor.109  The court also gave little weight to 
Sanofi’s evidence of synergistic effects for the combination, however the 
court found that those contentions, which included evidence that 
Tarka® was longer acting, more effective than a separate dosage, more 
effective in African American patients, and reduced the incidence of 
cardiac events, more than other compounds, the court did not give this 
much weight because the embodiment was narrower than the claims of 
the invention.110 
B.  Application to Formulations 
Another questionable application of the lead compound analysis is 
its application to patents on different chemical formulations.  A patent 
 
105.  See id. at *5 (“In determining whether a preliminary injunction should issue, we 
apply the four factor test set forth by the Supreme Court.  In general, a plaintiff seeking a 
preliminary injunction must establish [1] that he is likely to succeed on the merits, [2] that he 
is likely to suffer irreparable harm in the absence of preliminary relief, [3] that the balance of 
equities tips in his favor, and [4] that an injunction.”) (quoting Winter v. NRDC, Inc., 129 S. 
Ct. 365, 374 (2008)). 
106.  Id. at *8 (quoting Takeda Chem. Ind., Ltd. v. Alphapharm Pty., Ltd., 492 F.3d 
1350, 1357 (Fed. Cir. 2007)). 
107.  Id. at *8–*10. 
108.  Id. at *12.   
109.  Id.  
110.  Id. at *14.   
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on a chemical formulation is used widely for pharmaceutical patents to 
describe both the inactive and active ingredients of a drug, along with 
their relative compositions.  Patents on chemical formulations are also 
prevalent in many other areas not limited to formulations.  A 
formulation patent for a pharmaceutical was at issue in Unigene 
Laboratories v. Apotex.111  Unigene was the owner of the ‘392 patent112 
for nasal calitonin formulations.  The patent claimed a pharmaceutical 
composition of calcitonin, citric acid, phenyl ethyl alcohol, benzyl 
alcohol, and polysorbate in a specified concentration.113  The patent 
reported that the concentration conferred unexpected and beneficial 
properties when administered in that concentration.114  After Apotex 
submitted an Abbreviated New Drug Application (ANDA) for a 
generic of the commercial embodiment of the patent Fortical®, 
Unigene sued, asserting artificial infringement.115  Apotex argued that 
the patent was invalid as obvious and that the claim at issue would have 
been obvious based upon a large number of prior art teachings.116  
Apotex also asserted that obviousness could be based on a lead 
compound, Miacalcin, a compound similar to salmon calcitonin which 
consisted of a formulation including Miacalcin in about the same 
composition as the patent reported for salmon calcitonin.117  While 
ultimately rejecting Apotex’s obviousness argument,118 the court applied 
the lead compound analysis by concluding that Micalin was a lead 
compound for the development of similar drugs.119 
C.  Lead Compound Analysis and the Requirements of KSR 
Beyond its questionable applications, the lead compound 
obviousness analysis prompts another important question, that is, does 
anything warrant this special test after KSR?  The lead compound 
analysis began before the Supreme Court cautioned against rigid and 
inflexible approaches toward obviousness.120  The Supreme Court’s 
landmark KSR decision came down in 2007, but the Federal Circuit 
 
111.  Unigene Labs. v. Apotex, No. 06-CV-5572, 2009 WL 2762706 (S.D.N.Y.). 
112.  U.S. Patent No. 6,440, 392, Issued Aug. 27, 2002.  
113.  Id. at Col 6, l. 35–37. 
114.  Id. at Col. 7, l 20–22. 
115.  Unigene Labs., 2009 WL 2762706. 
116.  Id. at *7. 
117.  Id. 
118.  Id. at *15.   
119.  Id. at *7 n.11. 
120.  See KSR Int’l Co. v. Teleflex, 550 U.S. 398, 415 (2007). 
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cases before and after KSR show that the Federal Circuit’s analysis has 
changed little after KSR. 
In KSR v. Teleflex, a patent licensee alleged that a competitor 
infringed the licensed patent for an accelerator pedal assembly for 
vehicles.121  Automobile gas pedals control the rate at which gasoline 
and air enter the engine.122  In the 1970s, these petals were improved 
such that the pedal could be adjusted within an automobile’s footwell to 
accommodate small drivers.123  The prior art included adjustable pedal 
assemblies where both the pedals and the pivot points moved when the 
driver adjusted the footwell.  Regardless of the adjustability, pedals can 
interact with the throttle in two ways, either by a mechanical link or by a 
computer that detects the position of the petal and transmits that 
information to the throttle electronically.124  The Rixon patent revealed 
an adjustable pedal assembly with an electronic sensor mounted in the 
footpad of each pedal.125  The wires connecting the electronic sensors to 
the computer controlled throttle in the Rixon disclosure, however, were 
known to chafe as a result of the pedal arm’s movement. 
The patent at issue in KSR was the Engelgau patent which improved 
on the Rixon patent.  It disclosed a position-adjustable pedal assembly 
with an electronic pedal position sensor attached to the support 
assembly that allowed the sensor to remain in a fixed position while the 
driver adjusts the pedal.126  Not knowing of the Engelgau disclosure, 
General Motors Corporation asked KSR to supply adjustable pedal 
systems.127  Teleflex then notified KSR of the Engelgau patent and 
sought a licensing fee.  After negotiaiations broke down, the KSR 
challenged the patent’s validity on grounds of obviousness.128 
After the district court granted summary judgment in favor of KSR, 
holding that the patent was invalid as obvious, the Federal Circuit 
overturned.129  The Federal Circuit, in overturning the decision noted 
the powerful attraction of hindsight bias in the obviousness analysis.130  
 
121.  Teleflex, Inc. v. KSR Int’l Co., 298 F. Supp. 2d. 581 (E.D. Mich. 2003). 
122.  Daniel Becker, KSR v. Teleflex: How “Obviousness” has Changed, 4 DUKE J. 
CONST. L. & PP SIDEBAR 45, 46 (2009). 
123.  Id. 
124.  Id. at 46–47.   
125.  U.S. Patent No. 5,819,593 (filed Aug. 17, 1995). 
126.  U.S. Patent No. 6,109,241 (filed Jan. 26, 1999). 
127.  KSR Int’l Co. v. Teleflex, 550 U.S. 398, 410 (2007). 
128.  Teleflex, Inc. v. KSR Int’l Co., 298 F. Supp. 2d. 581, 587 (E.D. Mich. 2003). 
129.  Teleflex v. KSR Int’l Co., 119 F. App’x 282, 283 (Fed. Cir. 2005). 
130.  Id. at 288. 
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The Federal Circuit then noted that the best way to avoid the distortions 
of hindsight bias was to apply the court’s teaching-suggestion-
motivation test, which requires a court to make a specific finding of 
some teaching suggestion or motivation in the prior art to combine 
previous elements in the way asserted to be obvious.131 
The Supreme Court disagreed.132  The Supreme Court disagreed with 
several aspects of the Federal Court’s decision, but the main holding 
was that the Federal Circuit’s obviousness analysis was overly rigid and 
formulaic, and could not encompass the flexibility needed for an 
obviousness analysis.133  In overturning the Federal Circuit’s contention 
that the person of ordinary skill in the art would not have looked to a 
patent designed to solve a different problem, the court noted that the 
person of ordinary skill was also a person of ordinary creativity who 
could look at patents outside of the exact problem the person was trying 
to solve. 
Further, the court repudiated the Federal Circuit’s contention that 
proof that a combination would have been obvious to try could never be 
sufficient to establish obviousness.  To the contrary, the court held that 
when there are “a finite number of identified, predictable, solutions,” a 
person attempting to solve a problem will likely first try “known options 
within his or her technical grasp” and that the results obtained from this 
process, are merely those of “ordinary skill and common sense.”134 
KSR v. Teleflex was immediately recognized as a dramatic change to 
the obviousness landscape.135  After KSR, the bright line rule was that if 
there was no teaching, motivation, or suggestion in the prior art hinting 
at combining elements in the way the patent combined them, that the 
patent could not be invalidated as obvious.  Not only did the Supreme 
Court abolish the TSM test as the exclusive test for obviousness, the 
court emphasized that the correct approach to determining 
nonobviousness could not generally be contained in a rigid formula, 
rather the test was to be “expansive and flexible.”136  The Court also 
gave some additional features to the person of ordinary skill in the art.  
Now the PHOSITA has been given creativity and common sense to 
further heighten the standard for nonobviousness. 
 
131.  Id. at 290.  
132.  KSR Int’l Co. v. Teleflex, 550 U.S. 398, 415 (2007). 
133.  Id.  
134.  Id.  
135.  Becker, supra note 122, at 55. 
136.  KSR Int’l Co., 550 U.S. at 415. 
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Federal Circuit decisions employing the lead compound analysis 
have alluded to the doctrine’s consistency with KSR, but that 
consistency is questionable.  For example, the Federal Circuit in 
Takeda, a post-KSR case, squared the lead compound analysis with 
KSR’s directive to identify “a reason that would have prompted a 
person of ordinary skill in the relevant field to combine the elements in 
the way the claimed new invention does.”137  However, a closer look at 
KSR reveals the inconsistency of these two tests: KSR did not contain 
any rule concerning the motivation of the selection of the primary prior 
art references.  This additional hurdle is significant because it forces a 
party seeking to prove obviousness to demonstrate rationale for the 
prior art where that same showing would not be required in a 
mechanical context.  Moreover, the statutory interpretation where 
obviousness means one thing in one situation, and another in a different 
context is questionable.  The Supreme Court has previously warned 
against applying the same statutory text differently in different cases.138 
III.  TAKEAWAYS 
Understanding the nuances of the lead compound analysis and how 
it is likely to be applied by both the Federal Circuit and by district 
courts is important both in litigation challenging a patent’s 
nonobviousness of a chemical compound and for creating strong patent 
portfolios.  Furthermore, an understanding of where the lead compound 
analysis fails to capture the realities of drug discoveries can be useful in 
creating policies and practices for protecting chemical innovations 
where the lead compound analysis is unhelpful. 
One important take away from the cases is that the lead compound 
analysis greatly favors the patentee in most situations. A party 
challenging the obviousness of a chemical compound faces an uphill 
battle in showing both that there was a structurally similar compound 
that would have been considered a lead compound, and that there was a 
motivation to modify the compound. 
An important factor to understand for the lead compound analysis is 
what exactly a lead compound is and is not, as the court’s conception is 
 
137. Takeda Chem. Ind., Ltd. v. Alphapharm Pty., Ltd., 492 F.3d 1350, 1356–57 (Fed. 
Cir. 2007) (citing KSR, 550 U.S. at 418.). 
138.  See U.S. v. Santos, 553 US 507, 522–23 (2008) (“[T]he meaning of words in a 
statute cannot change with the statute’s application.  To hold otherwise, would render every 
statute a chameleon and would establish within our jurisprudence . . . the dangerous principle 
that judges can give the same statutory text different meanings in different cases.”) (citations 
and quotation marks omitted). 
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likely more narrow than a common sense understanding of the term 
lead compound.  While courts have been willing to say that there could 
be more than one lead compound, courts have generally assumed that 
there will be a small number in order for the choices to be sufficiently 
finite.  Thus, a party challenging a compound’s obviousness is really 
created with a Hobson’s choice.  They can assert that the compound is 
obvious based on several lead compounds, but if they assert too many, 
the court may decide that the choices were too numerous for any one 
compound to be considered lead. 
While there is no bright line for how many lead compounds there 
could be, the cases provide some illustrations of where the line may be 
from cases where courts have found a chemical compound obvious.  The 
court’s main consideration in looking at the number of potential leads 
comes from language in KSR that an important consideration for 
obviousness is when there are a “finite number of identified, predictable 
solutions.”139  The court has considered a compound lead when there are 
only a small number of other compounds.  In Altana Pharma v. Teva, 
for example, a compound was considered a lead compound when it was 
disclosed along with eighteen similar compounds.140  On the other end of 
the spectrum, when there are thousands of options, the court is unlikely 
to find a compound to be a lead compound.  For example, in Takeda, 
where the prior art reference disclosed millions of compounds including 
the compound at issue, the compound was not considered a lead 
compound.141 
Another important issue for parties considering litigation over a lead 
compound is when the compound is part of a formulation or a 
combination drug.  Thus far, there has been no clarity offered by the 
Federal Circuit on whether the lead compound analysis can be used in 
combination drugs or not or what would be considered the lead 
compound.  The district court cases show that the court may be willing 
to consider the structural similarity of components of mixtures.142  
Neither of the district court cases paint a clear picture of how the lead 
compound analysis might be used in conjunction with other elements.  
For example, even if the prima facie case was met for one component of 
 
139.  KSR Int’l Co., 550 U.S. at 421. 
140.  Altana Pharma AG v. Teva Pharm. USA, Inc., 566 F.3d 999, 1008 (Fed. Cir. 
2007). 
141.  Takeda, 492 F.3d at 1357 (Fed. Cir. 2007) 
142.  See, e.g., Sanofi-Aventis Deutschland GMBH v. Glenmark Pharms., No. 07-CV-
5855 (DMC), 2010 WL 2428561 (D.N.J.); Unigene Labs. v. Apotex, No. 06-CV-5572, 2009 
WL 2762706 (S.D.N.Y.). 
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a mixture, how would that affect the consideration of whether the 
combination of that element with other elements was met?  Will courts 
consider the structural similarity separately from the combination of 
elements?  Is there any precedent for such a bifurcation in the 
obviousness analysis?  These questions remain unanswered. 
Finally, what can be done when the prior art does disclose a lead 
compound?  For drugs that are developed based off a linear approach, 
patent protection may be available to those who show unexpected 
results, or teaching away.  The lead compound approach seemlingly 
failse to take into consideration situations where the sythesis is difficult 
or unavailable.  For example, in the case of gemcitibine, gemcitibine was 
recognized early on as a compound of particular relevance, but due to 
its functionality, the compound was not tested.143  The proposals had 
only failed because the compound proved so difficult to synthesize, and 
the lead compound analysis does not take this into consideration.  
Claims to the compound per se compound would be difficult to defend 
from a challenge under the current application of the lead compound 
analysis.  However, it seems unfitting that the availability of synthetic 
routes does not seem to be important to the lead compound analysis. 
IV. CONCLUSION 
Understanding the development and application of the Federal 
Circuit’s lead compound approach is to chemical obviousness is 
important for both prosecution and litigation practitioners in the 
chemical arts.  Understanding the Federal Circuit’s test, and how it has 
been used can be predictive in evaluating the strength of protection 
which may be available to claims to a compound per se, and even, to 
mixtures of componds.  Further, in light of KSR, future litigation may 
focus on whether the analysis is too rigid, and the Federal Circuit’s 
response may be important in the continuing development of the case 
law on obviousness. 
 
 
143.  Eli Lilly & Co. v. Sicor Pharm., 705 F. Supp. 2d, 971 (S.D. Ind. 2010). 
